Hyperparathyroidism (Primary)

1. Comprehensive Introduction & Overview

Primary Hyperparathyroidism (PHPT) is a prevalent endocrine disorder characterized by the autonomous, inappropriate hypersecretion of parathyroid hormone (PTH) from one or more of the four parathyroid glands. This surplus of PTH disrupts the body’s finely tuned calcium-phosphate homeostasis, leading to persistent hypercalcemia and hypophosphatemia.

Historically, PHPT was recognized primarily by overt skeletal and renal complications—the classic "bones, stones, abdominal groans, and psychic moans." However, in modern clinical practice, particularly in countries with robust biochemical screening, the disease is most frequently identified in asymptomatic patients via incidental hypercalcemia found on routine metabolic panels. Despite its ostensibly "asymptomatic" presentation, current research suggests that many patients experience subtle neurocognitive, cardiovascular, and skeletal impairments that warrant careful clinical consideration and, frequently, surgical intervention.

2. Etiology and Pathophysiology

The Mechanisms of Hypersecretion

The parathyroid glands act as the body’s "calcium sensor." Under normal physiological conditions, the Calcium-Sensing Receptor (CaSR) on the surface of parathyroid cells detects extracellular ionized calcium levels. When calcium is high, PTH secretion is inhibited. In PHPT, this feedback loop is fundamentally broken.

• Parathyroid Adenoma (80–85%): A solitary, benign tumor is the most common cause. It typically represents a monoclonal proliferation of parathyroid cells.
• Parathyroid Hyperplasia (10–15%): Involves multi-gland involvement, often associated with genetic syndromes such as Multiple Endocrine Neoplasia (MEN) type 1 or 2A.
• Parathyroid Carcinoma (<1%): An exceptionally rare malignancy characterized by severe hypercalcemia, a palpable neck mass, and significantly elevated PTH levels.

The PTH-Calcium Axis

Elevated PTH exerts its effects primarily on the kidneys and the skeleton:
1. Renal: PTH increases the reabsorption of calcium in the distal convoluted tubule and decreases phosphate reabsorption in the proximal tubule. It also stimulates the enzyme 1-alpha-hydroxylase, which converts inactive Vitamin D into its active form, 1,25-dihydroxyvitamin D (calcitriol), further increasing intestinal calcium absorption.
2. Skeletal: PTH stimulates osteoclast activity, leading to bone resorption and the release of calcium and phosphate into the extracellular fluid.

3. Clinical Presentation and Staging

Clinical Grading (The "Classic" vs. "Modern" Presentation)

Modern clinical practice differentiates between symptomatic and asymptomatic PHPT, though the latter is often a misnomer.

Symptom Clusters

• Renal: Nephrolithiasis (calcium oxalate stones) and nephrocalcinosis.
• Skeletal: Reduced bone mineral density (BMD), particularly at cortical sites (distal radius/wrist) compared to trabecular sites (lumbar spine).
• Neuropsychiatric: Fatigue, depression, anxiety, and impaired concentration.
• Gastrointestinal: Constipation, dyspepsia, and an increased risk of peptic ulcer disease.

4. Diagnostic Workup and Differential Diagnosis

Key Diagnostic Tests

A definitive diagnosis of PHPT requires the simultaneous measurement of serum calcium and intact PTH.

1. Biochemical Panel:
   • Serum Calcium: Usually elevated (or high-normal in normocalcemic variants).
   • Intact PTH: Inappropriately high or "normal" in the presence of hypercalcemia.
   • Serum Phosphate: Often low or low-normal.
   • 24-hour Urine Calcium: Crucial to rule out Familial Hypocalciuric Hypercalcemia (FHH).
2. Imaging (Pre-operative Localization):
   • Sestamibi Scan (99mTc-sestamibi): The gold standard for identifying hyperfunctioning glands.
   • Neck Ultrasound: High sensitivity for adenomas located near the thyroid.
   • 4D-CT Scan: Utilized in cases of re-operation or complex multi-gland disease.

Differential Diagnosis

The clinician must distinguish PHPT from other causes of hypercalcemia:
* Malignancy-associated hypercalcemia: Usually presents with low PTH and high PTHrP (PTH-related protein).
* Familial Hypocalciuric Hypercalcemia (FHH): Characterized by a low urinary calcium-to-creatinine clearance ratio (<0.01).
* Vitamin D Toxicity: High 25-hydroxyvitamin D levels.
* Granulomatous Diseases (e.g., Sarcoidosis): Elevated 1,25-dihydroxyvitamin D levels.

5. Long-term Prognosis and Management

Surgical Intervention: The Definitive Cure

Parathyroidectomy remains the only definitive cure for PHPT. Modern surgical techniques include:
* Focused Parathyroidectomy: Minimally invasive approach guided by pre-operative imaging and intraoperative PTH monitoring (IOPTH).
* Bilateral Neck Exploration: Reserved for cases where localization studies are negative or multi-gland disease is suspected.

Medical Management (For non-surgical candidates)

For patients who cannot or choose not to undergo surgery, medical management focuses on mitigating hypercalcemia and preventing bone loss:
* Hydration: Maintaining adequate fluid intake to prevent renal stones.
* Bisphosphonates: Useful for improving BMD, though they do not lower serum calcium.
* Calcimimetics (Cinacalcet): Increases the sensitivity of the CaSR to calcium, effectively lowering serum calcium levels without affecting bone density.

6. Risks, Side Effects, and Contraindications

While parathyroidectomy is generally safe, it carries specific risks:
* Recurrent Laryngeal Nerve Injury: Rare but can lead to vocal cord paralysis/hoarseness.
* Hungry Bone Syndrome: A post-operative drop in calcium levels caused by rapid bone remineralization, requiring aggressive calcium and Vitamin D supplementation.
* Hypoparathyroidism: Transient or permanent, necessitating calcium replacement.

7. Massive FAQ Section

Q1: Is asymptomatic PHPT really "asymptomatic"?

No. Recent data suggests that "asymptomatic" patients often report improved quality of life, reduced fatigue, and better cognitive function following successful parathyroidectomy.

Q2: What is the significance of the 24-hour urine collection?

It is critical to exclude FHH, a benign genetic condition that requires no surgery. If a patient with FHH is misdiagnosed with PHPT, they will undergo unnecessary surgery with no resolution of their hypercalcemia.

Q3: Why does PHPT cause kidney stones?

The high levels of circulating PTH increase calcium filtration at the kidneys. When this exceeds the renal threshold, the resulting hypercalciuria leads to the formation of calcium-based stones.

Q4: Can PHPT be cured by diet alone?

No. PHPT is a hormonal imbalance. Diet cannot override the autonomous secretion of PTH from the parathyroid glands.

Q5: What is the "Curative" threshold for intraoperative PTH?

The Miami criteria are widely used: a drop of >50% from the baseline PTH level 10 minutes after removal of the suspected adenoma indicates a successful procedure.

Q6: Does Vitamin D deficiency mask PHPT?

Yes. Severe Vitamin D deficiency can lower serum calcium levels, potentially masking the hypercalcemia of PHPT. Clinicians should normalize Vitamin D levels before confirming the absence of hypercalcemia.

Q7: Are there any specific medications to avoid if I have PHPT?

Thiazide diuretics should be used with extreme caution as they decrease urinary calcium excretion and can exacerbate hypercalcemia.

Q8: What is "Hungry Bone Syndrome"?

It is a post-operative complication where the bones, starved of calcium due to high PTH, rapidly absorb calcium from the blood, causing severe hypocalcemia. It is most common in patients with pre-existing bone disease.

Q9: How often should I monitor my calcium if I choose not to have surgery?

Patients managed conservatively should undergo biannual monitoring of serum calcium, creatinine, and annual DEXA scans to monitor bone density.

Q10: Does PHPT increase the risk of heart disease?

Emerging evidence suggests that PHPT is associated with an increased risk of hypertension, left ventricular hypertrophy, and vascular calcification, likely due to chronic hypercalcemia and PTH excess.

8. Summary Table: Clinical Indicators for Surgery

According to the International Workshop guidelines, surgery is generally recommended if one or more of the following are met:

Disclaimer: This guide is intended for professional informational purposes and does not constitute medical advice. Diagnosis and treatment of Hyperparathyroidism should be conducted by qualified endocrinologists and endocrine surgeons.